Skip to content

US · NCNA · BIOTECHNOLOGY

NuCana plc (NCNA) intrinsic value and stock valuation

$0.75as of 2026-11-21 · Mkt cap 8.14M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

NuCana plc DCF and intrinsic value

InvestorsCraft values NCNA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NCNA’s statements →

NuCana plc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Edinburgh, MD EH12 9DT nucana.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$0.00
20142025
Net income
-$-29.35M
20142025
Free cash flow
-$-7.66M
20142025
Total equity
$24.3M-24.5% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-20.11M-$-22.81M-$-32.78M-$-43.7M-$-45.34M
Net income-$-29.35M-$-19M-$-27.63M-$-32.02M-$-40.53M
EPSd-$-7.93M-$-3.2M-$-5.24M-$-6.13M-$-9.74M
Operating cash flow-$-7.47M-$-19.12M-$-26.44M-$-23.16M-$-23.82M
Capital expenditure-$-190K-$-290K-$-480K-$-520K-$-1.06M
Free cash flow-$-7.66M-$-19.41M-$-26.92M-$-23.68M-$-24.89M
Total assets$29.8M$14.8M$27.8M$58.3M$77.5M
Total debt$680K$190K$400K$640K$370K
Net debt-$-23.57M-$-6.56M-$-16.83M-$-41.27M-$-59.89M
Total equity$24.3M$5.95M$14.9M$38.5M$65.6M
Cash and short-term investments$24.3M$6.75M$17.2M$41.9M$60.3M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$12.7M$18M$25.1M$36.4M$36.8M
Selling, general and administrative expenses$8.1M$4.99M$6.06M$7.29M$8.53M
Other expenses-$-720K-$-100K$1.66M-$-4.59M$2.54M
Operating expenses$20.1M$22.9M$31.1M$43.7M$45.4M
Cost and expenses$20.1M$22.9M$31.1M$39.1M$47.9M
Interest income$390K$360K$750K$670K$100K
Interest expense$0.00$0.00$1.1M$0.00$0.00
Depreciation and amortization$270K$520K$570K$730K$940K
Ebitda-$-20.56M-$-22.48M-$-31.78M-$-52.15M-$-41.88M
Operating income-$-20.11M-$-22.81M-$-32.78M-$-43.7M-$-45.34M
Total other income/expenses, net-$-10.41M$360K$750K$5.24M-$-2.46M
Income before tax-$-30.52M-$-22.45M-$-32.03M-$-38.45M-$-47.8M
Income tax expense-$-1.17M-$-3.45M-$-4.4M-$-6.43M-$-7.27M
Net income-$-29.35M-$-19M-$-27.63M-$-32.02M-$-40.53M
Weighted average shares outstanding$3.7M$5.94M$5.27M$5.17M$4.16M
Weighted average diluted shares outstanding$3.7M$5.94M$5.27M$5.22M$4.16M
Balance sheet
20252024202320222021
Cash and short-term investments$24.3M$6.75M$17.2M$41.9M$60.3M
Net receivables$2.51M$4.64M$5.83M$50K$8.2M
Inventory$0.00$0.00$0.00$0.00-$-10K
Total current assets$26.9M$12.3M$25M$54.9M$71.6M
Property, plant and equipment, net$890K$200K$520K$870K$850K
Goodwill and intangible assets$2.96M$2.2M$2.13M$2.37M$2.41M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.97M$2.51M$2.79M$3.33M$5.86M
Total assets$29.8M$14.8M$27.8M$58.3M$77.5M
Accounts payable$520K$2.71M$3.38M$4.8M$1.83M
Short-term debt$40K$70K$210K$490K$410K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.79M$8.67M$12.7M$19.3M$11.7M
Long-term debt$660K$120K$190K$400K$160K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$710K$150K$250K$440K$210K
Capital lease obligations$680K$190K$400K$640K$370K
Total liabilities$5.51M$8.82M$12.9M$19.8M$11.9M
Common stock$14.3M$5.68M$2.11M$2.1M$2.09M
Retained earnings-$-252.33M-$-224.29M-$-207.71M-$-180.57M-$-149.73M
Accumulated other comprehensive income (loss)$87.1M$78.4M$79.2M$75.9M$72.1M
Total equity$24.3M$5.95M$14.9M$38.5M$65.6M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$680K$190K$400K$640K$370K
Net debt-$-23.57M-$-6.56M-$-16.83M-$-41.27M-$-59.89M
Cash flow statement
20252024202320222021
Net income-$-29.35M-$-19M-$-27.63M-$-32.02M-$-40.53M
Depreciation and amortization$270K$520K$570K$730K$940K
Stock-based compensation$10M$1.65M$3.86M$4.89M$6.66M
Change in working capital-$-3.67M-$-2.18M-$-1.28M$3.72M$4.09M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-2.18M-$-670K-$-1.43M$2.97M-$-430K
Net cash provided by operating activities-$-7.47M-$-19.12M-$-26.44M-$-23.16M-$-23.82M
Investments in property, plant and equipment-$-190K-$0.00-$0.00-$-520K-$-60K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$160K$80K$2.89M$120K-$-3.56M
Common stock issued$26.4M$8.73M$250K$70K$200K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$25M$8.18M-$-50K-$-160K-$-100K
Net change in cash$17.5M-$-10.48M-$-24.69M-$-18.35M-$-27.09M
Cash at end of period$24.3M$6.75M$17.2M$41.9M$60.3M
Operating cash flow-$-7.47M-$-19.12M-$-26.44M-$-23.16M-$-23.82M
Capital expenditure-$-190K-$-290K-$-480K-$-520K-$-1.06M
Free cash flow-$-7.66M-$-19.41M-$-26.92M-$-23.68M-$-24.89M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About NuCana plc

        NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.

        CEO
        Hugh Stephen Griffith
        Employees
        11
        Beta
        2.24

        Explore

        Frequently asked questions

        What is the intrinsic value of NuCana plc (NCNA)?

        InvestorsCraft does not currently publish an intrinsic value for NCNA. How the IC value is calculated.

        Is NCNA undervalued?

        InvestorsCraft does not publish an undervaluation signal for NCNA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.